Codexis, Inc. (0I0X.L)
USD 5.58
(-2.26%)
USD 5.58
(-2.26%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -49.28 Million USD | -57.21% |
| 2022 | -23.06 Million USD | -25.77% |
| 2021 | -16.75 Million USD | 5.11% |
| 2020 | -19.36 Million USD | -90.61% |
| 2019 | -7.99 Million USD | -11.1% |
| 2018 | -10.14 Million USD | 50.83% |
| 2017 | -21.92 Million USD | -168.22% |
| 2016 | -4.01 Million USD | -10.22% |
| 2015 | -2.36 Million USD | 59.34% |
| 2014 | -12.64 Million USD | 53.49% |
| 2013 | -31.07 Million USD | -34.65% |
| 2012 | -18.17 Million USD | -632.96% |
| 2011 | -4.83 Million USD | -408.14% |
| 2010 | 681 Thousand USD | 111.21% |
| 2009 | -12.05 Million USD | 68.16% |
| 2008 | -37.87 Million USD | -11.49% |
| 2007 | -35.67 Million USD | -116.54% |
| 2006 | -15.68 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -20.54 Million USD | -110.06% |
| 2024 Q3 | -13.68 Million USD | 33.95% |
| 2024 Q1 | -9.86 Million USD | -537.38% |
| 2023 FY | - USD | -57.21% |
| 2023 Q4 | 2.25 Million USD | 138.8% |
| 2023 Q2 | -9.73 Million USD | 58.62% |
| 2023 Q3 | -5.81 Million USD | 40.29% |
| 2023 Q1 | -23.52 Million USD | -240.05% |
| 2022 Q4 | -6.91 Million USD | 13.74% |
| 2022 Q3 | -8.01 Million USD | -207.36% |
| 2022 Q1 | -8.38 Million USD | 19.25% |
| 2022 Q2 | -2.6 Million USD | 68.89% |
| 2022 FY | - USD | -25.77% |
| 2021 Q3 | 1.33 Million USD | 142.77% |
| 2021 Q1 | -7.84 Million USD | -100.08% |
| 2021 Q4 | -10.38 Million USD | -880.83% |
| 2021 FY | - USD | 5.11% |
| 2021 Q2 | -3.11 Million USD | 60.37% |
| 2020 Q4 | -3.92 Million USD | 20.49% |
| 2020 FY | - USD | -90.61% |
| 2020 Q2 | -6.1 Million USD | 21.98% |
| 2020 Q1 | -7.82 Million USD | -727.38% |
| 2020 Q3 | -4.93 Million USD | 19.22% |
| 2019 Q2 | -5.52 Million USD | -5.4% |
| 2019 Q3 | 259 Thousand USD | 104.69% |
| 2019 FY | - USD | -11.1% |
| 2019 Q1 | -5.23 Million USD | -713.51% |
| 2019 Q4 | -946 Thousand USD | -465.25% |
| 2018 Q1 | -4.46 Million USD | -608.42% |
| 2018 Q4 | -644 Thousand USD | 64.16% |
| 2018 FY | - USD | 50.83% |
| 2018 Q3 | -1.79 Million USD | 49.71% |
| 2018 Q2 | -3.57 Million USD | 20.05% |
| 2017 Q1 | -7.15 Million USD | -36.19% |
| 2017 Q3 | -9.79 Million USD | -60.34% |
| 2017 Q2 | -6.1 Million USD | 14.56% |
| 2017 FY | - USD | -168.22% |
| 2017 Q4 | 879 Thousand USD | 108.97% |
| 2016 Q3 | 2.7 Million USD | -23.88% |
| 2016 FY | - USD | -10.22% |
| 2016 Q4 | -5.25 Million USD | -294.23% |
| 2016 Q2 | 3.55 Million USD | 162.61% |
| 2016 Q1 | -5.67 Million USD | -154.01% |
| 2015 FY | - USD | 59.34% |
| 2015 Q2 | -4.33 Million USD | 21.63% |
| 2015 Q1 | -5.52 Million USD | -1328.67% |
| 2015 Q3 | 5.69 Million USD | 231.32% |
| 2015 Q4 | -2.23 Million USD | -139.24% |
| 2014 Q1 | -6.39 Million USD | 35.02% |
| 2014 Q2 | -8.91 Million USD | -39.32% |
| 2014 Q3 | -4.25 Million USD | 52.25% |
| 2014 Q4 | 450 Thousand USD | 110.58% |
| 2014 FY | - USD | 53.49% |
| 2013 Q1 | -9.63 Million USD | 38.85% |
| 2013 Q2 | -9.86 Million USD | -2.43% |
| 2013 Q3 | -6.6 Million USD | 33.05% |
| 2013 Q4 | -9.84 Million USD | -49.05% |
| 2013 FY | - USD | -34.65% |
| 2012 Q4 | -15.74 Million USD | -1634.8% |
| 2012 FY | - USD | -632.96% |
| 2012 Q1 | -4.05 Million USD | -122.86% |
| 2012 Q3 | 1.02 Million USD | 149.95% |
| 2012 Q2 | -2.05 Million USD | 49.36% |
| 2011 Q1 | -460 Thousand USD | -119.77% |
| 2011 Q2 | -5.2 Million USD | -1031.52% |
| 2011 Q3 | 590 Thousand USD | 111.34% |
| 2011 Q4 | -1.82 Million USD | -408.47% |
| 2011 FY | - USD | -408.14% |
| 2010 Q3 | -439 Thousand USD | 66.31% |
| 2010 Q1 | 766 Thousand USD | 125.64% |
| 2010 Q4 | 2.32 Million USD | 630.07% |
| 2010 FY | - USD | 111.21% |
| 2010 Q2 | -1.3 Million USD | -270.1% |
| 2009 FY | - USD | 68.16% |
| 2009 Q1 | -4.26 Million USD | 15.74% |
| 2009 Q4 | -2.98 Million USD | 21.51% |
| 2009 Q3 | -3.8 Million USD | -282.23% |
| 2009 Q2 | -996 Thousand USD | 76.66% |
| 2008 Q4 | -5.06 Million USD | 0.0% |
| 2008 FY | - USD | -11.49% |
| 2008 Q1 | -11.3 Million USD | 0.0% |
| 2007 Q1 | -4.44 Million USD | 0.0% |
| 2007 FY | - USD | -116.54% |
| 2006 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | -107.639% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 71.946% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 78.99% |
| Organovo Holdings, Inc. | -14.8 Million USD | -232.858% |